A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia

Pharmacotherapy

Volumn 18, Issue 4, 1998, Pages 836-839

  Rindone, Joseph P ^a   Hiller, Debra ^a   Arriola, Greg ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET THERAPY; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, MONOUNSATURATED; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; INDOLES; LIPOPROTEINS, LDL; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; TREATMENT OUTCOME; URINARY RETENTION;

EID: 0031873289     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. The West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1310-17.
2. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Rindone JP, Achacoso R, Bledsoe R. Effect of lovastatin administered every other day on serum low-density lipoprotein cholesterol > 160 mg/dl. Am J Cardiol 1995;76:312-13.
4. Dennis VC, Britton ML, Sirmans SM, Letassy NA, Freeman DA. The use of alternate-day lovastatin in hypercholesterolemic men. Ann Pharmacother 1997;31:708-12.
5. Expert Panel of the of the National Cholesterol Education Program. Summary of the second report of the of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel 11). JAMA 1993;269:3015-23.
6. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
7. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. Clin Pharmacol Ther 1986;39:489-90.
8. Havel RJ, Hunninghake DB, Illingworth R, et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. Ann Intern Med 1987;107:609-15.
9. Illingworth DR, Sextron GJ. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J Clin Invest 1984;74:1972-8.
10. Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Ann Pharmacother 1995;29:743-59.
11. Insull W, Dujovne BD, Hosking JD, et al. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia. Arch Intern Med 1994;154:2449-55.
12. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319;24-33.
13. Traber MG, Kayden HJ. Inhibition of cholesterol synthesis by mevinolin stimulates low density lipoprotein receptor activity in human monocyte-derived macrophages. Atherosclerosis 1984;52:1-11.
14. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365-74.
15. Pekkanen J, Linn S, Heiss G, et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990;322:1700-7.
16. The Post-Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-62.
17. Sandoz Pharmaceuticals. Lescol (fluvastatin) package insert. East Hanover, NJ;1996.
18. Sprecher DL, Abrams J, Allen JW, et al. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med 1994;120:537-43.
19. Flethcher SW, Pappius EM, Harper SJ. Measurement of medication compliance in a clinical setting. Comparison of three methods in patients prescribed digoxin. Arch Intern Med 1979;139:635-8.
20. Rudd P, Byyny RL, Zachary V, et al. Pill count measures of compliance in a drug trial: variability and suitability. Am J Hypertens 1988;1:309-12.
21. Abramovicz M, ed. Choice of lipid-lowering drugs. Med Lett 1996;38:67-70.